Tasca Therapeutics

About Tasca Therapeutics

Tasca Therapeutics is focused on leveraging a unique drug discovery platform to identify and map novel lipid-binding pockets on proteins, with the goal of developing new medicines to treat cancer patients.

Products & Services

CP-383:A treatment for advanced solid tumors, currently in Phase 1/2 dose escalation and expansion trial.

Small Molecule Inhibitors:Developed for multiple oncology indications.

Specialties

Drug Discovery Platform Lipid-Binding Pocket Mapping Oncology Small Molecule Inhibitors

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 52000000 MR: - FA: $52 million FAN: 52000000	D: 2024-12-10 FD: 2024-12-10	3 investors

Series A Latest

2024-12-10

$52.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Milenko Cicmil

Chief Executive Officer

S

Susan Doleman

VICE PRESIDENT OF CLINICAL OPERATIONS

S

Susanne Saalau

Senior Director Biochemistry and Biophysics

D

Drew King

Acting Chief Financial Officer

V

Valerie Jansen

Acting Chief Medical Officer/Clinical Lead

K

Kenzie MacIsaac

Acting Chief Data Officer, Partner

View 20 more team members with Pro

Unlock Full Team Directory

Recent News